Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Verrica Pharmaceuticals Inc. - Common Stock
(NQ:
VRCA
)
8.240
-0.190 (-2.25%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Verrica Pharmaceuticals Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
May 24, 2022
Gainers
Via
Benzinga
The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures
↗
May 24, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
'Pharma Bro' Martin Shkreli Says He Toyed With Crypto On Uniswap — Vitalik Buterin Reacts
↗
May 22, 2022
Martin Shkreli, who infamously raised the price of an antiparasitic drug by 5,455% in 2017, sang praises of Ethereum (CRYPTO: ETH)-based decentralized cryptocurrency exchange Uniswap (UNI) after...
Via
Benzinga
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More
↗
May 22, 2022
Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support.
Via
Benzinga
Recap: Verrica Pharmaceuticals Q1 Earnings
↗
May 09, 2022
Verrica Pharmaceuticals (NASDAQ:VRCA) reported its Q1 earnings results on Monday, May 9, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
↗
April 26, 2022
During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
Via
Benzinga
7 Biotech Stocks With Key Catalysts for May
↗
May 11, 2022
The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns.
Via
InvestorPlace
Stocks That Hit 52-Week Lows On Wednesday
↗
May 04, 2022
During Wednesday's trading, 435 companies set new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
↗
January 18, 2022
Tuesday morning saw 454 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Unilever (NYSE:UL) was the largest firm by market cap to set a...
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
↗
May 03, 2022
Tuesday's session saw 211 companies set new 52-week lows.
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates
↗
May 01, 2022
The month of April was a mixed one for regulatory approvals. The Food and Drug Administration delayed approvals for at least three treatment candidates. New molecular entity, or NME, approvals, a...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2022
↗
March 10, 2022
Upgrades For Alpha Metallurgical Resources Inc (NYSE:AMR), B. Riley Securities upgraded the previous rating of Neutral to Buy. For the fourth quarter, Alpha Metallurgical...
Via
Benzinga
The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street
↗
December 16, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug...
Via
Benzinga
FDA Accepts Verrica's Resubmission For VP-102 For Contagious Skin Disease
↗
December 16, 2021
The FDA has accepted Verrica Pharmaceuticals Inc's (NASDAQ: VRCA) resubmitted marketing application seeking approval for VP-102 to treat molluscum contagiosum (...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
December 15, 2021
Gainers Calliditas Therapeutics (NASDAQ:
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
↗
October 01, 2021
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new...
Via
Benzinga
10 Biggest Price Target Changes For Wednesday
↗
September 22, 2021
Piper Sandler boosted the price target for Adobe Inc. (NASDAQ: ADBE) from $600 to $670. Adobe shares fell 3.5% to $623.50 in pre-market trading. Keybanc reduced the price target...
Via
Benzinga
50 Biggest Movers From Yesterday
↗
September 22, 2021
Check out these big penny stock gainers and losers Losers Edesa Biotech, Inc. (NASDAQ: EDSA) shares dipped 29.9% to close at $8.36 on profit-taking after the stock...
Via
Benzinga
Mid-Afternoon Market Update: Dow Edges Lower; Helbiz Shares Spike Higher
↗
September 21, 2021
Toward the end of trading Tuesday, the Dow traded down 0.11% to 33,932.34 while the NASDAQ rose 0.18% to 14,740.41. The S&P also fell, dropping 0.09% to 4,353.81. The U.S. has...
Via
Benzinga
Topics
Stocks
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
September 21, 2021
Gainers Corvus Pharmaceuticals (NASDAQ:CRVS) stock moved upwards by 30.95% to $8.08 during Tuesday's regular session. As of 12:30 EST, this security is trading at a...
Via
Benzinga
Mid-Day Market Update: Gold Rises 1%; Verrica Pharmaceuticals Shares Slide
↗
September 21, 2021
Midway through trading Tuesday, the Dow traded up 0.44% to 34,119.86 while the NASDAQ rose 0.66% to 14,810.89. The S&P also rose, gaining 0.43% to 4,376.48. The U.S. has the...
Via
Benzinga
Topics
Stocks
32 Stocks Moving In Tuesday's Mid-Day Session
↗
September 21, 2021
Gainers Helbiz, Inc. (NASDAQ: HLBZ) shares jumped 177.4% to $39.83. Helbiz Media, the media arm of Helbiz announced a deal with Amazon Italy, a unit of Amazon.com. ReWalk...
Via
Benzinga
Why Verrica Pharmaceuticals Stock Is Getting Pummeled Today
↗
September 21, 2021
The Food and Drug Administration delivered some bad news regarding the company's dermatology candidate.
Via
The Motley Fool
Why Verrica Pharmaceuticals Shares Are Trading Lower Today
↗
September 21, 2021
Verrica Pharmaceuticals (NASDAQ:VRCA) shares are trading lower after the company announced the FDA issued a Complete Response Letter regarding its New Drug Application...
Via
Benzinga
Mid-Morning Market Update: Markets Gain; AutoZone Earnings Beat Views
↗
September 21, 2021
Following the market opening Tuesday, the Dow traded up 0.14% to 34,017.77 while the NASDAQ rose 0.39% to 14,771.47. The S&P also rose, gaining 0.18% to 4,365.67. The U.S. has...
Via
Benzinga
Topics
Earnings
Stocks
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
September 21, 2021
Gainers Viridian Therapeutics (NASDAQ:VRDN) shares rose 18.05% to $12.62 during Tuesday's pre-market session. The company's market cap stands at $120.9 million....
Via
Benzinga
Verrica Pharma Shares Slide After Response Letter From FDA
↗
September 21, 2021
The FDA has issued a Complete Response Letter (CRL) regarding Verrica Pharmaceuticals Inc's (NASDAQ: VRCA) marketing application seeking approval for VP-...
Via
Benzinga
18 Stocks Moving in Tuesday's Pre-Market Session
↗
September 21, 2021
Gainers ReWalk Robotics Ltd. (NASDAQ: RWLK) rose 37% to $1.78 in pre-market trading after declining around 4% on Monday. ReWalk Robotics, last month, reported Q2 sales of $1.44...
Via
Benzinga
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
↗
September 21, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Cerevel Therapeutics...
Via
Benzinga
The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight
↗
September 19, 2021
Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.